Natural Phenomenon or Process – Page 7

AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback

7 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, Malignant neoplasm of prostate, Metastatic to, Phase 3 Clinical Trials, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).

AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion

7 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, CAPItello-281, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, Phase 3 trial, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)

Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events

7 months ago talkbio0Tagged Cardiovascular system, cholesterol, Eli, Eli Lilly, Lipoprotein(a ), Lp(a ), Muvalaplin, oral drug, Phase 2 Clinical Trials, Risk

Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction

Gilead Sciences Announces Layoffs at California HQ and Closure of Seattle Office

7 months ago talkbio0Tagged Biopharma, California, Gilead Sciences, HQ, Office Closure

Gilead Sciences, layoffs, California HQ, Seattle office closure, biopharma, workforce reduction

Sensei Biotherapeutics Announces Major Restructuring: 46% Workforce Reduction and Closure of Rockville Research Site

7 months ago talkbio0Tagged Clinical Development, Organization administrative structures, Research Site Closure, restructuring, Sensei Biotherapeutics, SNS-101

Sensei Biotherapeutics, workforce reduction, research site closure, organizational restructuring, SNS-101 clinical development

Marinus Pharmaceuticals Cuts 45% of Workforce Following Clinical Setbacks

7 months ago talkbio0Tagged clinical setbacks, ganaxolone, Marinus Pharmaceuticals, Refractory status epilepticus, Seizures, Tuberous Sclerosis

Marinus Pharmaceuticals, layoffs, workforce reduction, clinical setbacks, ganaxolone, seizures, tuberous sclerosis complex (TSC), refractory status epilepticus (RSE)

FDA Authorizes LumiThera’s Valeda Light Delivery System for Dry AMD Treatment

7 months ago talkbio0Tagged authorization, Desiccation, Glycogen storage disease type II, LumiThera, photobiomodulation, United States Food and Drug Administration, Valeda Light Delivery System

FDA authorization, Valeda Light Delivery System, dry AMD treatment, photobiomodulation, LumiThera

Sinaptica’s Neuromodulation Therapy Demonstrates 44% Reduction in Alzheimer’s Disease Progression

8 months ago talkbio0Tagged Alzheimer 's disease, Default Mode Network, Disease Progression, neuromodulation therapy, Non-invasive therapy, Personalized Treatment, Sinaptica, Stimulation procedure, Structure of precuneus

Sinaptica Therapeutics, Neuromodulation therapy, Alzheimer’s disease, Disease progression reduction, Personalized treatment, Non-invasive therapy, Default Mode Network (DMN), Precuneus stimulation